Alternative fuels for cancer cells

Cancer Journal (United States)

Volumn 21, Issue 2, 2015, Pages 49-55

  Keenan, Melissa M ^a   Chi, Jen Tsan ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acetate; alternative fuels; amino acids; lactate; macromolecules; nonglucose nutrients; oncogenic mutations; tumor cells; tumor glycolysis; tumor microenvironmental stresses; Tumormetabolism

Indexed keywords

ACETIC ACID; AMINO ACID; GLUTAMINE; LACTIC ACID; NITROGEN;

AUTOPHAGY; CANCER CELL; CARBON SOURCE; CELL ENERGY; CELL GROWTH; CELL METABOLISM; CELL STRESS; CELL SURVIVAL; GENE MUTATION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; MACROMOLECULE; METABOLIC STRESS; METABOLISM; MURINE MODEL; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR METABOLISM; TUMOR MICROENVIRONMENT; ADAPTATION; ANIMAL; CELL TRANSFORMATION; ENERGY METABOLISM; GENETICS; PHYSIOLOGICAL STRESS;

ADAPTATION, BIOLOGICAL; AMINO ACIDS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; GLUTAMINE; HUMANS; LACTIC ACID; NEOPLASMS; PHENOTYPE; STRESS, PHYSIOLOGICAL;

EID: 84926636884     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000104     Document Type: Review

References (75)

1. Song CW, Clement JJ, Levitt SH. Preferential cytotoxicity of 5-thio-Dglucose against hypoxic tumor cells.J NatlCancer Inst. 1976;57:603-605.
2. Lampidis TJ, Kurtoglu M, Maher JC, et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol. 2006;58:725-734.
3. Tang X, Lucas JE, Chen JL, et al. Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. Cancer Res. 2012;72:491-502.
4. Chen JL, Merl D, Peterson CW, et al. Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet. 2010;6:e1001093.
5. Chen JL, Lucas JE, Schroeder T, et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 2008; 4:e1000293.
6. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961-967.
7. Harding HP, Zhang Y, ZengH, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003; 11:619-633.
8. Kovacevic Z,Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 1972;32:326-333.
9. Yuneva M, Zamboni N, Oefner P, et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178:93-105.
10. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105: 18782-18787.
11. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762-765.
12. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69:7986-7993.
13. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010; 70:8981-8987.
14. Kung HN, Marks JR, Chi JT. Glutamine synthetase Is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 2011;7:e1002229.
15. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481: 380-384.
16. Mullen AR,WheatonWW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481: 385-388.
17. Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18: 207-219.
18. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35:427-433.
19. Boza JJ, Moennoz D, Bournot CE, et al. Role of glutamine on the de novo purine nucleotide synthesis in Caco-2 cells. Eur J Nutr. 2000;39:38-46.
20. Duan S, Pagano M. Linking metabolism and cell cycle progression via the APC/CCdh1 and SCFbetaTrCP ubiquitin ligases. Proc Natl Acad Sci U S A. 2011;108:20857-20858.
21. Reid MA, Wang WI, Rosales KR, et al. The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013;50:200-211.
22. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role ofmitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem. 1984;259:6215-6221.
23. Sauer LA, Dauchy RT, Nagel WO. Identification of an NAD(P)+-dependent 'malic' enzyme in small-intestinal-mucosal mitochondria. Biocheml J. 1979;184:185-188.
24. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496: 101-105.
25. Lamonte G, Tang X, Chen JL, et al. Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. In: Cancer Metab. 2013;1:23.
26. Evans K, Nasim Z, Brown J, et al. Acidosis-sensing glutamine pump SNAT2 determines amino acid levels and mammalian target of rapamycin signalling to protein synthesis in L6 muscle cells. J Am Soc Nephrol. 2007;18:1426-1436.
27. Moret C, Dave MH, Schulz N, et al. Regulation of renal amino acid transporters during metabolic acidosis. Am J Physiol Renal Physiol. 2007;292: F555-F566.
28. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657-663.
29. Sheen JH, Zoncu R, Kim D, et al. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell. 2011;19:613-628.
30. Scott L, Lamb J, Smith S, et al. Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells. Br J Cancer. 2000;83:800-810.
31. KreisW, Baker A, Ryan V, et al. Effect of nutritional and enzymatic methionine deprivation upon human normal and malignant cells in tissue culture. Cancer Res. 1980;40:634-641.
32. Ohtawa K, Ueno T,Mitsui K, et al. Apoptosis of leukemia cells induced by valine-deficient medium. Leukemia. 1998;12:1651-1652.
33. Chung WJ, Lyons SA, Nelson GM, et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 2005;25:7101-7110.
34. Doxsee DW, Gout PW, Kurita T, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007; 67:162-171.
35. Lo M, Ling V, Wang YZ, et al. The xc-cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464-472.
36. Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCTantiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450-465.
37. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of systemxc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.
38. Shiraki N, Shiraki Y, Tsuyama T, et al. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab. 2014;19:780-794.
39. Shyh-Chang N, Locasale JW, Lyssiotis CA, et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science. 2013;339:222-226.
40. Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11:671-677.
41. Lucas JE, Kung HN, Chi JT. Latent factor analysis to discover pathwayassociated putative segmental aneuploidies in human cancers. PLoS Comput Biol. 2010;6:e1000920.
42. Gatza ML, Kung HN, Blackwell KL, et al. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res. 2011;13:R62.
43. Sonveaux P, Copetti T, de Saedeleer CJ, et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One. 2012;7:e33418.
44. Vegran F, Boidot R,Michiels C, et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71:2550-2560.
45. Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabologenomics. Cell Cycle. 2011;10:1271-1286.
46. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916-921.
47. Quennet V, Yaromina A, Zips D, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 2006;81:130-135.
48. Kennedy KM, Scarbrough PM, Ribeiro A, et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS One. 2013;8:e75154.
49. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118: 3930-3942.
50. De Saedeleer CJ, Porporato PE, Copetti T, et al. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration. Oncogene. 2014;33:4060-4068.
51. Boidot R, Vegran F,Meulle A, et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012;72:939-948.
52. Perez de Heredia F,Wood IS, Trayhurn P. Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflugers Arch. 2010;459:509-518.
53. Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011;108: 16663-16668.
54. Wolfe AJ. The acetate switch. Microbiol Mol Biol Rev. 2005;69:12-50.
55. Wellen KE, Hatzivassiliou G, Sachdeva UM, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324: 1076-1080.
56. Mashimo T, Pichumani K, Vemireddy V, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159: 1603-1614.
57. Comerford SA, Huang Z, Du X, et al. Acetate dependence of tumors. Cell. 2014;159:1591-1602.
58. Schug ZT, Peck B, Jones DT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27:57-71.
59. Commisso C,Davidson SM, Soydaner-Azeloglu RG, et al.Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633-637.
60. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857-902.
61. Kasahara K, Nakayama Y, Sato I, et al. Role of Src-family kinases in formation and trafficking of macropinosomes. J Cell Physiol. 2007;211: 220-232.
62. Bar-Sagi D, Feramisco JR. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science. 1986;233: 1061-1068.
63. Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20:1193-1198.
64. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
65. Payton S. Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma. Nat Rev Urol. 2013;10:431.
66. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-269.
67. Beadle GW, Tatum EL. Genetic control of biochemical reactions in Neurospora. Proc Natl Acad Sci U S A. 1941;27:499-506.
68. Sitter B, Lundgren S, Bathen TF, et al. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006;19:30-40.
69. Budczies J, Denkert C, Muller BM, et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue-a GCTOFMS based metabolomics study. BMC Genomics. 2012;13:334.
70. Borgan E, SitterB, LingjaerdeOC, et al.Merging transcriptomics and metabolomics- advances in breast cancer profiling.BMCCancer. 2010;10:628.
71. Brauer HA, Makowski L, Hoadley KA, et al. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res. 2013;19:571-585.
72. Tang X, Lin CC, Spasojevic I, et al. A joint analysis of metabolomics and genetics of breast cancer. Breast Cancer Res. 2014;16:415.
73. Gorrini C, Baniasadi PS, Harris IS, et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med. 2013;210: 1529-1544.
74. Kaadige MR, Looper RE, Kamalanaadhan S, Ayer DE. Glutaminedependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci U S A. 2009.
75. Marin-Valencia I, Yang C, Mashimo T, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15: 827-837.